Navigation Links
EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
Date:1/23/2013

attractive and logical treatment for sarcoma."

Ken K. Ren , Ph.D., EntreMed's Chief Executive Officer commented, "We are excited about the initiation of this trial.  We believe ENMD-2076 has good potential in the treatment of sarcoma along with other oncology indications.  In our Phase 1 trial in solid tumors, we had one patient with advanced/metastatic sarcoma relapse after multiple lines of previous therapies, however after being treated with ENMD-2076, the patient had prolonged disease PFS for 21 months.  This Phase 2 trial will enable us to explore the potential of ENMD-2076 for this indication further. We look forward to our continued advancement and development of ENMD-2076 as an oncology platform."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed, Inc. recently announced the initiation of a Phase 2 study of ENMD-2076 in triple-negative breast cancer and the initiation of a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in additi
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
2. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
3. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
4. EntreMed Reports Second Quarter 2012 Financial Results
5. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
6. EntreMed Reports First Quarter 2012 Financial Results
7. HemaTerra Announces New Quality Control Product For Blood Centers
8. Quest Announces Battery-Powered Mobile Wireless Surgical Video Display Solution
9. HOLOGIC ANNOUNCES ORGANIZATIONAL CHANGES TO ITS DIAGNOSTICS SEGMENT; INTEGRATION OF GEN-PROBE PROCEEDING AHEAD OF SCHEDULE
10. BioElectronics Announces South Korean Patent Allowance for its Innovative OTC Pain Relief Medical Devices
11. GenScript Announces Joint Road Show with Open Monoclonal Technology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  ResMed ... availability of the ResMed Data Exchange program, a ... home medical equipment (HME) and other health care ... timely, secure access to critical patient information. It ... ResMed,s AirView™ and U-Sleep™ patient management platforms with ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5ResMed Launches ResMed Data Exchange 2
... , RICHMOND, Va., Nov. 4 Filtrona Porous Technologies, ... for the medical device and healthcare industry, and a ... recently developed a unique foam-fiber hybrid component for select ... Referred to as MediSponge® RBR , the patent-pending ...
... Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management ... non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and ... today that it has initiated a clinical study of ... in patients with Type 1 and Type 2 diabetes. ...
Cached Medicine Technology:Filtrona Porous Technologies Realizes Innovative New Product Development Through Foam-Fiber Technology Synergy : Introducing MediSponge(R) RBR Wound Care Dressings 2Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients 2Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients 3
(Date:10/22/2014)... Plano, Texas (PRWEB) October 22, 2014 ... convenience of completing their continuing education at home ... now have access to 20 brand new, premium ... HomeCEUConnection.com’s robust catalog of over 2,000 hours ... to fully customize their educational experience. With such ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... By Dennis Thompson ... -- U.S. health officials on Monday officially tightened guidelines for ... with no skin exposure and use of a respirator at ... Prevention decided to issue the tougher rules after two Dallas ... diagnosed in the United States, Liberian national Thomas Eric Duncan. ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... Celebrate you" health fair will provide free, health screenings ... WICHITA, Kan., July 30 As summer vacation slowly ... the return to school.,Getting ready to go back to ... To help parents, the "Celebrate,Your Children, Celebrate You," health ...
... treated for breast cancer did not know that their odds ... whether they undergo mastectomy or breast conserving surgery. Minority women ... factor of their treatment decision, according to a study from ... were also less likely to know about relative survival rates ...
... July 30 Dyadem today announced that ... Hofliger, a Germany-based builder of,production equipment for ... FMEA-Med software to help its customers minimize ... of its specialized,pharmaceutical equipment., Harro Hofliger ...
... conjunction,with DURECT Corporation,s (Nasdaq: DRRX ) second ... to listen to the conference call,that will be ... 6, 2008,at 9:00 a.m. EDT (6:00 a.m. PDT)., ... audio webcast of the presentation will be available ...
... Joins Premier Professional Online Medical Resource as ... ... The Doctor,s Channel, (http://www.thedoctorschannel.com ), today announced the appointment of ... Contributing Editor. Hailed by CNBC as the "educational,YouTube" for doctors, ...
... of Love Canal Are Not Counted In the NY State,Department ... What Have We Learned?, FALLS CHURCH, Va., July 30 ... Environment & Justice:, WHAT:, Press Conference & walking ... once stood., Rain or Shine, WHEN:, Friday, ...
Cached Medicine News:Health News:UniCare Health Plan Teams With Local Organizations for Community and Wellness Fair 2Health News:Minorities less likely to know about breast cancer treatment options 2Health News:Minorities less likely to know about breast cancer treatment options 3Health News:Harro Hofliger Reduces Risk in Pharmaceutical Manufacturing Equipment with Dyadem 2Health News:Harro Hofliger Reduces Risk in Pharmaceutical Manufacturing Equipment with Dyadem 3Health News:DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call 2Health News:The Doctor's Channel Adds Esteemed Director of Minimally Invasive Urology at Columbia University to Editorial Team 2Health News:The Doctor's Channel Adds Esteemed Director of Minimally Invasive Urology at Columbia University to Editorial Team 3Health News:30 Years After State of Emergency Declared at Love Canal, NY Closing the 99th Street School Triggering the Federal Superfund Program; Schools & Communities Across the Nation Still at Risk of Toxic Contamination 2
...
... steel construction for lifelong quality. Sealed hydraulic ... chair movement. Soft, contoured cushions with heavy-duty ... counter-balanced slit lamp arm for easy, smooth, ... slit lamp arm for easy access to ...
Our Ophthalmic Diagnostic Sets offer everything an eye care specialist needs. Complete your set with your choice of ophthalmoscope, retinoscope, handle, and case....
3.5v Coaxial Ophthalmoscope Set with Convertible Handle and Hard Case. Our 3.5v Coaxial Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
Medicine Products: